December 3rd, 2012
Selections from Richard Lehman’s Literature Review: December 3rd
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the association between aldosterone-antagonist therapy and mortality and readmission among patients with HF and reduced EF, warfarin therapy after bioprosthetic AVR, and more.
November 14th, 2010
Emphatic Support for Eplerenone in NYHA Class II Heart Failure
Larry Husten, PHD
Aldosterone antagonists have proven beneficial in heart failure patients with moderate-to-severe symptoms and in MI patients with LV dysfunction and heart failure. Now EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) has extended these benefits to patients with systolic HF and mild symptoms. EMPHASIS HF randomized 2737 patients with NYHA class II […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?